Research

Ligand's Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential

9 days ago   |   By Xconomy

Ligand Pharmaceuticals is adding neurological disease and cystic fibrosis programs to its pipeline through a deal to acquire assets from drug discovery company Icagen. San Diego-based Ligand is paying $15 million up front for the “core assets” of Icagen's Durham, NC operations. The neuroscience program is being developed under a partnership with Roche while the cystic fibrosis research is a collaboration with the Cystic Fibrosis Foundation. The transaction also includes six unpartnered Icagen programs. Under the deal terms, Icagen stands to gain up to $25 million more depending on whether...
Read more ...

 


Search by Tags

   Research      Pharmaceutical      Drugs      Neurology      Discovery      Drug      Neurosciences      Neuroscience      Pharmaceuticals      National blog main      Raleigh-Durham blog main      Raleigh-Durham top stories      San Diego      San Diego blog main      San Diego top stories      Astellas      Biotech      Bristol-myers Squibb      Cystic Fibrosis      Cystic Fibrosis Foundation      Deals      Drug discovery      Icagen      Ion channels      Life Sciences      Ligand Pharmaceuticals      Pfizer      Roche      Vernalis  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce's $88M & More

Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce's $88M & More

The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin... Read more ...

MyoNet: A Transfer-learning based LRCN for Lower Limb Movement Recognition...

MyoNet: A Transfer-learning based LRCN for Lower Limb Movement Recognition and Knee Joint Angle Prediction for Remote Monitoring of Rehabilitation Progress from sEMG

The clinical assessment technology such as remote monitoring of rehabilitation progress for lower limb related ailments rely on the automatic evaluation of movement performed... Read more ...

Feasibility of using high-contrast grating as a point-of-care sensor for...

Feasibility of using high-contrast grating as a point-of-care sensor for therapeutic drug monitoring of immunosuppressants

Abstract Point-of-care testing has demonstrated great transformative potential in personalized medicine. In particular, patients undergoing transplantation require POC testing... Read more ...

Development Of Low-Cost Point-Of-Care Technologies For Cervical Cancer...

Development Of Low-Cost Point-Of-Care Technologies For Cervical Cancer Prevention Based On A Single-Board Computer

Cervical cancer disproportionally affects women in low- and middle-income countries, in part due to the difficulty of implementing existing cervical cancer screening and... Read more ...

SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal

SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal

Since a major restructuring at Five Prime Therapeutics in October that kicked off a wind-down of most of its research and preclinical efforts, the company has been looking to... Read more ...

Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug

Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug

Spruce Biosciences has raised $88 million to advance clinical testing of a drug for a rare inherited endocrine disorder that can lead to a potentially life-threatening hormonal... Read more ...

COVID-19 Vaccine Will Close in on the Spikes

COVID-19 Vaccine Will Close in on the Spikes

As epidemiologists try to stay ahead of the spread of new coronavirus COVID-19, vaccine developers, like Sanofi and Johnson & Johnson , are focusing on the “spike” proteins... Read more ...

Brain cells protect muscles from wasting away

Several processes in the roundworm C. elegans boost the stress response in cells, incidentally making worms resistant to a high-fat diet and extending their lifespan... Read more ...

103967 Laboratory Research Assistant

PSYCHIATRY/HNRP Salary commensurate with qualifications and experienceFiling Deadline: Fri 3/6/2020... Read more ...

Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global...

SAN DIEGO, Feb. 21, 2020 - Sorrento Therapeutics, Inc. , announced today that it will present at LEERINK Partners 9th Annual Global Healthcare Conference on Thursday...... Read more ...